The good news is that a solvent-free, less toxic chemo drug can add seven months to the lives of women with metastatic breast cancer, compared to another drug that's more toxic and is solvent-based. A recent study shows that Abraxane is better than Taxotere. According to the press release, The study was supported by Abraxis BioScience, which manufactures Abraxane. Gradishar [the researcher] is a member of the advisory boards for Abraxis and sanofi-aventis U.S., which manufactures Taxotere. He has received grant support from Abraxis and sanofi-aventis.
Which is a neat solution to the problem of researcher bias/payola. Get money from both pharmaceutical companies, so then no one can accuse you of selling influence.
A recent study of oncologists showed that the doctors said they themselves weren't influenced by gifts from pharmaceutical companies, but they thought that others might be.